London-based Global Healthcare Opportunities (or GHO Capital Partners) a European healthcare specialist investor, has appointed David Miller and Geoffrey Hamilton-Fairley as operating partners.

Both Miller and Hamilton-Fairley have extensive operational experience and professional networks to support deal origination, as well as knowledge of GHO’s portfolio companies, with many of which they already have working relationships.

Miller was formerly senior vice-president of global market access at Biogen with responsibility for the global pricing, reimbursement and access of Biogen’s product portfolio, before founding his own advisory practice whose clients have included large, midsize and start-up biotechs.

Hamilton-Fairley has experience of investing in, and leading, companies at different stages of development from start-ups through to sale and IPO, with particular experience within medtech and advanced therapies. His experience includes developing and guiding Oncimmune, a company pioneering technologies to enable early cancer detection, from a Nottingham University start-up through to an IPO in May 2016.

In a statement the GHO’s partners said: “We are pleased to welcome David and Geoffrey to our team at what is an exciting time for the firm. Their track record within the industry speaks for itself, and we look forward to working closely with them both to support our existing portfolio and identify new opportunities. Against a difficult backdrop, GHO continues to see strong investor demand, built on robust performance from our portfolio and a busy pipeline of bolt-on and platform investment activity.”

Miller said: “GHO is unquestionably the reference player in European healthcare. I am delighted to have the opportunity to work with their portfolio, who represent some of the industry’s fastest-growing, most innovative and highest-quality companies in the market today.”

Hamilton-Fairley added: “With the world’s spotlight increasingly on healthcare and life sciences, the GHO team has already shown it targets the best opportunities and guides them with expertise to expedite their progress. I am looking forward to bringing together promising companies in medtech and advanced therapeutics with the capital and guidance they need to further enhance the GHO portfolio.”